Biogen To Pay $900M To Settle Qui Tam Suit Alleging Kickbacks Involving 3 MS Drugs
BOSTON — Drug manufacturer Biogen Inc. has agreed in principle to pay $900 million to settle a whistleblower’s lawsuit that it paid kickbacks to health care professionals to prescribe the company’s...To view the full article, register now.
Already a subscriber? Click here to view full article